Published in Arthritis Rheum on May 01, 1998
Cancer-related inflammation. J Clin Immunol (2012) 1.91
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A (2002) 1.55
Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood (2005) 1.32
Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol (2001) 1.29
Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum (2011) 1.24
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther (2006) 1.19
Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol (2011) 1.19
Critical advances in septicemia and septic shock. Crit Care (2000) 1.16
Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol (2003) 1.12
D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 1.01
Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine (2013) 0.98
Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis. Proc Natl Acad Sci U S A (2011) 0.97
Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function. J Biol Chem (2009) 0.92
The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis (2015) 0.91
Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int (2011) 0.87
Identification of NURR1 as a mediator of MIF signaling during chronic arthritis: effects on glucocorticoid-induced MKP1. Am J Pathol (2010) 0.87
Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect Immun (2005) 0.86
The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and lethality. Am J Pathol (2007) 0.85
Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine (2009) 0.85
Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol (2008) 0.85
Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clin Exp Immunol (2008) 0.84
Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clin Exp Immunol (1999) 0.84
Hypoxia and glucocorticoid signaling converge to regulate macrophage migration inhibitory factor gene expression. Arthritis Rheum (2009) 0.84
Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis (2003) 0.83
Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. Microcirculation (2009) 0.83
Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol (2014) 0.81
Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine (2015) 0.81
Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients. PLoS One (2014) 0.81
Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinase-dependent signaling pathway. Korean J Intern Med (2010) 0.80
Macrophage migration inhibitory factor inhibits the antiinflammatory effects of glucocorticoids via glucocorticoid-induced leucine zipper. Arthritis Rheumatol (2014) 0.80
Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases. Arthritis (2010) 0.80
Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis. Rheumatol Int (2013) 0.79
A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection. J Cell Mol Med (2008) 0.79
Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin. Clin Exp Immunol (2010) 0.79
Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med (2016) 0.78
The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD. PLoS One (2016) 0.77
Immunohistochemical study of lymphoid tissues in adjuvant arthritis (AA) by image analysis; relationship with synovial lesions. Clin Exp Immunol (2000) 0.76
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. Ann Rheum Dis (2007) 0.76
Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1β production in a murine model of acute gout. J Leukoc Biol (2016) 0.76
Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: EVIDENCE FOR PARTIAL ALLOSTERIC AGONISM IN COMPARISON WITH CXCL12 CHEMOKINE. J Biol Chem (2016) 0.76
Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol (2001) 7.40
Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med (2000) 6.62
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 3.70
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol (1997) 3.05
[Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref]. Rev Saude Publica (2000) 3.01
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med (1997) 2.98
Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States). Cancer Causes Control (1999) 2.75
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem (1999) 2.60
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A (1997) 2.53
Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest (1981) 2.41
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A (1997) 2.36
Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum (1994) 2.30
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun (2002) 2.21
The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med (1996) 2.21
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 2.17
Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol (1999) 2.11
An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med (1999) 2.10
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene (2007) 2.08
Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. J Exp Med (1978) 2.02
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
Enterovirus replication in valvular tissue from patients with chronic rheumatic heart disease. Eur Heart J (2002) 1.98
Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1996) 1.95
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J (2001) 1.91
The macrophagen in human rapidly progressive glomerulonephritis. Lancet (1976) 1.88
Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun (1998) 1.87
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol (1997) 1.86
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer (2009) 1.82
Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A (2005) 1.79
De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res (2000) 1.78
Epidemiological studies of leukaemia in children and young adults around nuclear facilities: a critical review. Radiat Prot Dosimetry (2008) 1.77
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A (1999) 1.74
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene (2006) 1.68
Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol (2001) 1.68
Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int (1997) 1.66
Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet (1996) 1.63
Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol (1998) 1.63
Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol (1993) 1.60
Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med (1995) 1.55
Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci U S A (1984) 1.55
Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet (1994) 1.55
Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci U S A (1998) 1.51
Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest (1991) 1.49
Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma (1999) 1.49
Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest (1998) 1.46
Role of CFTR mutations in adult bronchiectasis. Thorax (2004) 1.46
Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med (2000) 1.44
Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun (2007) 1.43
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
[Transitory hyperinsulinism with hypoglycemia in asphyxia neonatorum]. Arch Pediatr (1997) 1.40
De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol (1996) 1.40
Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene (2008) 1.40
Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry (1997) 1.40
Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (1992) 1.40
Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol (2000) 1.38
Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. Rheumatology (Oxford) (2003) 1.38
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med (1997) 1.38
Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol (1997) 1.37
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun (2000) 1.37
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators. J Med Chem (1992) 1.36
T lymphocyte participation in antibody-induced experimental glomerulonephritis. Kidney Int (1985) 1.36
Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol (1995) 1.35
Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol (1997) 1.35
Antibody independent crescentic glomerulonephritis in mu chain deficient mice. Kidney Int (1997) 1.35
Videotape reliability of the third revised edition of the K-SADS. J Am Acad Child Adolesc Psychiatry (1989) 1.33
Marked differences between two isoforms of human pyruvate dehydrogenase kinase. J Biol Chem (2000) 1.32
Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A (1996) 1.32
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia (2006) 1.32
Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet (1988) 1.32